Want to join the conversation?
Jon Groberg of UBS asks about the outlook for 2017. $A said it has a rich pipeline of new product introductions coming in 4Q16 and in FY17. $A expects pharma and China markets to be significant growth drivers but believes they will be below double digit levels. $A is forecasting low single digit growth for FY17.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.